T cells and T-cell receptors in acute renal failure  by Portilla, Didier & Okusa, Mark D.
208   Kidney International (2006) 69
commentar y
See original article on page 233
T cells and T-cell receptors in acute 
renal failure
Didier Portilla1 and Mark D Okusa2
T cells are activated by antigen-independent as well as antigen-
dependent mechanisms during ischemia-reperfusion injury to the 
kidney. In the current issue, a study by Savransky et al. suggests that 
antigen-dependent activation of T-cell receptors further contributes 
to the pathogenesis of ischemia-reperfusion injury.
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Although the participation of lymphocytes 
in kidney ischemia-reperfusion injury (IRI) 
has gained recent interest, there are con-
siderable gaps in our knowledge. Insight 
into the kinetics of T-cell infi ltration and 
into the way these cells participate in the 
classical paradigm of T-cell activation has 
remained elusive. Th ere is evidence indicat-
ing that antigen-independent activation of 
T cells occurs through cytokines and reac-
tive oxygen intermediates. However, in this 
issue, Savransky et al.1 report on a series of 
experiments that suggest that T-cell recep-
tors (TCRs) participate in the pathogen-
esis of IRI, thus potentially advancing our 
knowledge of how the innate and adaptive 
immune systems participate in IRI.
Ischemia-reperfusion injury: innate and 
adaptive immune system
The rapid appearance within kidney 
tissue of components of the innate 
immune system, such as neutrophils and 
macrophages, following IRI provides 
clear support for an antigen-independ-
ent mechanism of tissue injury.2,3 The 
innate immune system has evolved as a 
host defense mechanism that recognizes 
microbial products. Toll-like receptors 
and a limited number of other receptors 
appear to respond to highly conserved 
structures referred to as pathogen-asso-
ciated molecular patterns that are released 
by microbes or apoptotic or necrotic tissue 
components.4 Once activated, an infl am-
matory and immune response leads to 
leukocyte sequestration in infl amed sites, 
complement activation, and eradication 
of pathogen through cytokines, comple-
ment/membrane attack complex, and 
natural killer cells. Activation of kidney 
resident dendritic cells leads to a pheno-
typic switch from an immature cell type 
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characterized by high phagocytic capac-
ity, low class II major histocompatibility 
complex, and co-stimulatory proteins to 
a mature cell type characterized by low 
phagocytic capacity, high surface expres-
sion of class II major histocompatibility 
complex, and co-stimulatory molecules, 
thereby permitting T-cell activation.5–7 
Th us, in addition to antigen-independ-
ent activation of T cells through reactive 
oxygen species, interferon-γ, and other 
cytokines, antigen-dependent activa-
tion of T cells may occur through anti-
gen presentation by dendritic cells, the 
major antigen-presenting cell (APC) in 
the kidney. In a recent study, Dong et al.8 
demonstrated activated traffi  cking of den-
dritic cells following IRI by showing their 
capacity to migrate to the kidney draining 
lymph node, leading to antigen presenta-
tion and activation of naive T cells. Aft er 
T-cell activation and proliferation, these 
T cells may participate in the later phases 
of IRI.
Signals involved in T-cell activation 
during acute renal failure
Th e mechanisms of T-cell activation have 
not been completely elucidated. A general 
property of lymphocytes, including T cells, 
is the need for two distinct extracellular 
signals (TCR signal and co-stimulatory 
signal) in order to induce proliferation 
and diff erentiation into eff ector cells. Th e 
fi rst signal is provided by antigen binding 
to the major histocompatibility complex 
molecules in the APCs. In the case of 
T cells, peptide major histocompatibility 
complex binding to the TCR and CD4 and 
CD8 co-receptors provides signal 1. How-
ever, the antigen-specifi c clonal expansion 
of naive T cells requires a second co-stimu-
latory signal that must be delivered by the 
same APC on which the T cell recognizes 
its specifi c antigen. Th e best-character-
ized co-stimulatory molecules on APCs 
are the structurally related glycoproteins 
B7.1 (CD80) and B7.2 (CD86), which 
are also called B7 molecules. The B7 
molecules are homodimeric members of 
the immunoglobulin superfamily, found 
exclusively on the surface of cells capable 
of stimulating T-cell growth. Th e receptor 
for B7 molecules on the T cell is CD28, 
another member of the immunoglobu-
lin superfamily. Ligation of CD28 by B7 
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Figure 1 | Two-signal model of lymphocyte activation. Signal 1 corresponds to the binding 
of the peptide-MHC complex of the antigen-presenting cell to the T-cell receptor. Signal 2 
corresponds to the binding of the B7 molecule in the antigen-presenting cell, its CD28 receptor 
in the T cell.
molecules or by anti-CD28 antibodies will 
co-stimulate the growth of naive T cells, 
and antibodies to the B7 molecules, which 
inhibit their binding to CD28, inhibit T-
cell responses. On naive T cells, CD28 is 
the only receptor for B7 molecules. Once 
T cells are activated, however, they express 
an additional receptor called cytotoxic 
T lymphocyte-associated antigen 4 
(CTLA-4). CTLA-4 closely resembles 
CD28 in sequence, and the two mole-
cules are encoded by closely linked genes. 
CTLA-4 binds B7 molecules about 20 
times more avidly than CD28 does and 
appears to deliver a negative signal to the 
activated T cell. Th us, binding of CTLA-
4 to B7 molecules plays an essential role 
in limiting the proliferative response of 
activated T cells to antigen and B7 on the 
surface of APCs. Recent studies9 have 
identifi ed programmed death-1 (PD-1) as 
a new member of the CD28 family, and as 
a negative regulator of the immune system. 
PD-1 interacting with ligands PD-L1 (B7-
H1) and PD-L2 (B7-DC) can accelerate 
graft  arterial disease in cardiac allograft s.
Accumulating evidence supports the 
role of T cells in the pathogenesis of IRI. 
T cells participate not only in IRI limited 
to the kidney, but also in IRI of other 
organs, such as the liver and heart.10 
Th us, T cells appear to undergird a fun-
damental mechanism in the pathogenesis 
of organ IRI. Biopsies of human kidneys 
have demonstrated the presence of lym-
phocytes in acute tubular necrosis.11 
Indirect evidence for the role of T lym-
phocytes in ischemic acute renal failure 
comes from several studies showing that 
lymphocyte-related cytokines are upreg-
ulated in the post-ischemic kidney. Th e 
use of genetically modifi ed T cell-defi cient 
mice, including CD4–/–, CD4/CD8–/–, 
nu/nu, and Rag1–/– mice,12–14 is associ-
ated with attenuation of renal injury aft er 
IRI. Other indirect evidence for the role of 
T cells in ARF came from the blocking of 
one of the co-stimulatory pathways nec-
essary for T-cell activation. Blockade of 
the B7–CD28 co-stimulation pathway by 
CTLA-4 immunoglobulin, a recombinant 
fusion protein containing the extracellu-
lar domain of human CTLA-4, resulted in 
T-cell anergy, ameliorated renal dysfunc-
tion, and decreased mononuclear-cell 
infi ltration in renal cold ischemia.15
Not all studies, however, support the role 
of T cells in renal IRI. Renal protection 
was not seen aft er IRI in CD8–/– mice16 
or in mice given anti-neutrophil antibody 
(GK1.5).17 In addition, two other studies 
demonstrated that Rag1–/– mice did not 
show protection from renal IRI.18,19 Anti-
neutrophil serum may induce secondary 
eff ects that could sensitize kidneys to IRI. 
Th e use of knockout mice has been some-
what controversial, which attests to the 
complexities of these genetically modifi ed 
mice. For example, other cell types, such 
as natural killer cells, natural killer T cells, 
and B cells, could compensate for the lack 
of T cells and adaptively respond to gene 
depletion. Despite these diff erences, the 
strongest data that support the role of T 
cells in IRI come from adoptive transfer 
studies. Studies by Burne et al.16 in nu/nu 
mice and by Day et al.14 in Rag1–/– mice 
show that these mice are protected when 
subjected to IRI. However, tissue injury is 
restored with CD4+ reconstitution.
An important question is whether T-
cell activation in IRI can occur through 
antigen presentation to TCRs by APCs. 
To address this question, Savransky et 
al.1 investigated the potential role of the 
TCR in IRI. Th e authors examined the 
eff ects of αβ and γδ TCR defi ciency on 
ischemic acute renal failure. Th ey found 
that TCR-αβ-defi cient mice, which lack 
single-positive CD4+ and CD8+ cells 
but contain double-positive CD4/CD8 
cells,20 had improved survival, decreased 
renal dysfunction, and decreased tubular 
injury aft er IRI compared with wild-type 
littermates. Th ese results are consistent 
with previous studies supporting the role 
of T cells in functional and structural 
processes associated with IRI. TCR-γδ-
defi cient mice also had slightly reduced 
mortality, renal dysfunction, and struc-
tural injury when compared with wild-
type mice, but the reduction was not as 
marked as in TCR-αβ-defi cient mice. Less 
tubular injury in proximal convoluted 
tubules, the proximal straight segment, 
and the inner stripe of the medulla was 
observed in TCR-αβ- and TCR-γδ-defi -
cient mice compared with wild-type mice. 
Th e reduced expression of the cytokines 
tumor necrosis factor-α and interleukin-6 
further suggests that these cytokines are 
potential mediators of a TCR-mediated 
eff ect. Th us, these studies complement 
previous studies and support the concept 
that TCRs may contribute to T-cell activa-
tion during IRI.
A recent study by Faubel et al., how-
ever, did not confirm these results.17 
In this study, renal IRI led to a similar 
degree of injury in TCR-αβ–/– mice as 
compared with control mice. The dis-
crepancy between these findings and 
those of Savransky et al.1 is unexplained. 
Additional studies will be needed to shed 
light on the role of TCRs in IRI. For exam-
ple, reconstitution studies could add sig-
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nifi cant support for the roles of TCR-αβ 
and TCR-γδ. In these experiments, T cells 
harboring TCR-αβ or TCR-γδ could be 
isolated from wild-type mice by use of 
specifi c monoclonal antibodies and used 
to reconstitute the defi cient host mice. 
Savransky et al.1 found relatively mild 
protection when TCR-αβ- and TCR-γδ-
deficient mice were subjected to renal 
IRI. Th erefore, combined tissue-specifi c 
T-cell defi ciency of both αβ and γδ could, 
in future studies, provide more robust dif-
ferences in response to IRI. Th ese studies 
could further demonstrate the magnitude 
at which these receptors contribute to the 
pathogenesis of IRI. Th us, until additional 
studies are performed, we are left  with the 
tantalizing but unconfi rmed possibility 
that TCRs may be activated in an antigen-
dependent manner aft er IRI.
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